BridgeBio Pharma (BBIO) Stock Forecast, Price Target & Predictions
BBIO Stock Forecast
BridgeBio Pharma stock forecast is as follows: an average price target of $45.00 (represents a 93.63% upside from BBIO’s last price of $23.24) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
BBIO Price Target
BBIO Analyst Ratings
Buy
BridgeBio Pharma Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Oct 24, 2024 | David Lebowitz | Citigroup | $45.00 | $24.17 | 86.18% | 93.63% |
Oct 17, 2024 | Mani Foroohar | Leerink Partners | $46.00 | $26.34 | 74.64% | 97.93% |
Sep 11, 2024 | Biren Amin | Piper Sandler | $46.00 | $28.78 | 59.83% | 97.93% |
Sep 03, 2024 | Salim Syed | Mizuho Securities | $53.00 | $29.92 | 77.14% | 128.06% |
Jun 24, 2024 | Danielle Brill | Raymond James | $46.00 | $22.64 | 103.14% | 97.93% |
Jun 05, 2024 | Kostas Biliouris | BMO Capital | $37.00 | $26.93 | 37.42% | 59.21% |
Jun 05, 2024 | Tiago Fauth | Wells Fargo | $58.00 | $27.13 | 113.79% | 149.57% |
May 30, 2024 | Paul Choi | Goldman Sachs | $50.00 | $27.61 | 81.09% | 115.15% |
May 28, 2024 | Eliana Merle | UBS | $47.00 | $27.94 | 68.22% | 102.24% |
May 20, 2024 | Raghuram Selvaraju | H.C. Wainwright | $43.00 | $30.09 | 42.90% | 85.03% |
10
BridgeBio Pharma Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 1 | 4 | 11 |
Avg Price Target | $45.00 | $47.50 | $47.36 |
Last Closing Price | $23.24 | $23.24 | $23.24 |
Upside/Downside | 93.63% | 104.39% | 103.79% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Oct 24, 2024 | Citigroup | Buy | Buy | Hold |
Oct 02, 2024 | Oppenheimer | - | Perform | Initialise |
Sep 24, 2024 | BMO Capital | Market Perform | Market Perform | Hold |
Sep 11, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Sep 04, 2024 | Piper Sandler | - | Overweight | Initialise |
Sep 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Jun 24, 2024 | Raymond James | Outperform | Outperform | Hold |
Jun 24, 2024 | Evercore ISI | Outperform | Outperform | Hold |
Jun 10, 2024 | Cowen & Co. | Buy | Buy | Hold |
Jun 05, 2024 | BMO Capital | Outperform | Outperform | Hold |
10
BridgeBio Pharma Financial Forecast
BridgeBio Pharma Revenue Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.09M | $1.64M | $1.83M | $1.87M | $338.00K | $73.75M | $1.69M | $12.89M | $2.34M | $54.02M | $462.00K | $122.00K | $8.13M |
Avg Forecast | $126.70M | $111.30M | $136.50M | $72.60M | $61.02M | $37.35M | $33.20M | $37.45M | $4.65M | $1.68M | $3.96M | $7.26M | $4.55M | $3.62M | $2.99M | $3.23M | $4.52M | $4.09M | $27.19M | $4.70M | $21.56M | $15.80M | $28.49M | $27.51M | $16.93M | $10.75M |
High Forecast | $609.99M | $535.85M | $657.17M | $349.53M | $293.76M | $179.81M | $159.85M | $78.58M | $19.00M | $8.07M | $3.96M | $7.26M | $7.30M | $3.62M | $14.41M | $15.56M | $21.78M | $4.09M | $27.19M | $4.70M | $21.56M | $15.80M | $28.49M | $27.51M | $16.93M | $10.75M |
Low Forecast | $8.26M | $7.26M | $8.90M | $4.73M | $3.98M | $2.44M | $2.16M | $4.63M | $236.70K | $109.24K | $3.96M | $7.26M | $995.98K | $3.62M | $195.16K | $210.69K | $295.01K | $4.09M | $27.19M | $4.70M | $21.56M | $15.80M | $28.49M | $27.51M | $16.93M | $10.75M |
# Analysts | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 6 | 8 | 4 | 2 | 2 | 4 | 9 | 7 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 6 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.13% | 0.55% | 0.57% | 0.41% | 0.08% | 2.71% | 0.36% | 0.60% | 0.15% | 1.90% | 0.02% | 0.01% | 0.76% |
Forecast
BridgeBio Pharma EBITDA Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 6 | 8 | 4 | 2 | 2 | 4 | 9 | 7 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 6 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-157.69M | $-146.10M | $-117.61M | $-112.89M | $-113.71M | $27.70M | $-156.44M | $-130.52M | $-144.60M | $-82.82M | $-151.98M | $-109.02M | $-104.93M |
Avg Forecast | $-126.70M | $-111.30M | $-136.50M | $-72.60M | $-61.02M | $-37.35M | $-33.20M | $-37.45M | $-4.65M | $-1.68M | $-3.96M | $-119.34M | $-4.55M | $-3.62M | $-2.99M | $-127.64M | $-120.47M | $-4.09M | $-27.19M | $-136.51M | $-21.56M | $-15.80M | $-28.49M | $-67.77M | $-16.93M | $-10.75M |
High Forecast | $-8.26M | $-7.26M | $-8.90M | $-4.73M | $-3.98M | $-2.44M | $-2.16M | $-4.63M | $-236.70K | $-109.24K | $-3.96M | $-95.47M | $-995.98K | $-3.62M | $-195.16K | $-102.11M | $-96.37M | $-4.09M | $-27.19M | $-109.21M | $-21.56M | $-15.80M | $-28.49M | $-54.22M | $-16.93M | $-10.75M |
Low Forecast | $-609.99M | $-535.85M | $-657.17M | $-349.53M | $-293.76M | $-179.81M | $-159.85M | $-78.58M | $-19.00M | $-8.07M | $-3.96M | $-143.21M | $-7.30M | $-3.62M | $-14.41M | $-153.17M | $-144.56M | $-4.09M | $-27.19M | $-163.81M | $-21.56M | $-15.80M | $-28.49M | $-81.33M | $-16.93M | $-10.75M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 43.51% | 48.81% | 0.92% | 0.94% | 27.83% | -1.02% | 1.15% | 6.05% | 9.15% | 2.91% | 2.24% | 6.44% | 9.76% |
Forecast
BridgeBio Pharma Net Income Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 6 | 8 | 4 | 2 | 2 | 4 | 9 | 7 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 6 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-177.00M | $-157.90M | $-176.85M | $-155.97M | $-148.42M | $59.37M | $-246.71M | $-167.42M | $-155.94M | $-96.35M | $-163.08M | $-119.98M | $-115.86M |
Avg Forecast | $-143.27M | $-152.69M | $-122.53M | $-182.86M | $-164.48M | $-180.97M | $-181.39M | $-179.50M | $-207.67M | $-189.14M | $-188.16M | $-134.57M | $-163.79M | $-149.56M | $-150.58M | $-143.93M | $-135.84M | $-181.61M | $-104.42M | $-153.93M | $-165.43M | $-171.56M | $-182.26M | $-72.72M | $-161.35M | $-168.41M |
High Forecast | $30.84M | $32.86M | $26.37M | $39.36M | $35.40M | $38.95M | $39.04M | $-154.46M | $-174.68M | $40.71M | $40.50M | $-107.66M | $-137.93M | $-116.33M | $32.41M | $-115.14M | $-108.67M | $-181.61M | $-104.42M | $-123.15M | $-165.43M | $-171.56M | $-182.26M | $-58.18M | $-161.35M | $-168.41M |
Low Forecast | $-853.70M | $-909.86M | $-730.14M | $-1.09B | $-980.07M | $-1.08B | $-1.08B | $-223.34M | $-246.49M | $-1.13B | $-1.12B | $-161.49M | $-200.00M | $-184.64M | $-897.27M | $-172.71M | $-163.01M | $-181.61M | $-104.42M | $-184.72M | $-165.43M | $-171.56M | $-182.26M | $-87.27M | $-161.35M | $-168.41M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.18% | 1.05% | 1.23% | 1.15% | 0.82% | -0.57% | 1.60% | 1.01% | 0.91% | 0.53% | 2.24% | 0.74% | 0.69% |
Forecast
BridgeBio Pharma SG&A Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 6 | 8 | 4 | 2 | 2 | 4 | 9 | 7 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 6 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $35.78M | $36.12M | $31.11M | $31.86M | $31.19M | $36.43M | $43.71M | $54.75M | $46.08M | $45.97M | $45.41M | $37.44M | $36.02M |
Avg Forecast | $1.03B | $907.66M | $1.11B | $592.06M | $497.60M | $304.58M | $270.77M | $305.38M | $37.88M | $13.66M | $32.30M | $59.20M | $37.09M | $29.56M | $24.41M | $26.35M | $36.90M | $33.33M | $221.73M | $38.29M | $175.85M | $128.85M | $232.30M | $20.25M | $138.07M | $87.67M |
High Forecast | $4.97B | $4.37B | $5.36B | $2.85B | $2.40B | $1.47B | $1.30B | $640.84M | $154.96M | $65.78M | $32.30M | $59.20M | $59.56M | $29.56M | $117.52M | $126.87M | $177.65M | $33.33M | $221.73M | $38.29M | $175.85M | $128.85M | $232.30M | $24.30M | $138.07M | $87.67M |
Low Forecast | $67.37M | $59.18M | $72.58M | $38.60M | $32.44M | $19.86M | $17.65M | $37.79M | $1.93M | $890.85K | $32.30M | $59.20M | $8.12M | $29.56M | $1.59M | $1.72M | $2.41M | $33.33M | $221.73M | $38.29M | $175.85M | $128.85M | $232.30M | $16.20M | $138.07M | $87.67M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.21% | 1.48% | 1.18% | 0.86% | 0.94% | 0.16% | 1.14% | 0.31% | 0.36% | 0.20% | 2.24% | 0.27% | 0.41% |
Forecast
BridgeBio Pharma EPS Forecast
Quarter
Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 6 | 8 | 4 | 2 | 2 | 4 | 9 | 7 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 6 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-1.16 | $-1.04 | $-1.00 | $0.40 | $-1.69 | $-1.15 | $-1.06 | $-0.66 | $-1.18 | $-1.01 | $-0.98 |
Avg Forecast | $-0.76 | $-0.81 | $-0.65 | $-0.97 | $-0.87 | $-0.96 | $-0.96 | $-0.95 | $-1.10 | $-1.00 | $-1.00 | $-0.74 | $-0.87 | $-0.79 | $-0.80 | $-0.82 | $-0.84 | $-0.97 | $-0.56 | $-1.09 | $-0.88 | $-0.91 | $-0.97 | $-0.75 | $-0.86 | $-0.90 |
High Forecast | $0.16 | $0.17 | $0.14 | $0.21 | $0.19 | $0.21 | $0.21 | $-0.82 | $-0.93 | $0.22 | $0.21 | $0.16 | $-0.73 | $-0.62 | $0.17 | $0.18 | $0.18 | $-0.97 | $-0.56 | $-1.09 | $-0.88 | $-0.91 | $-0.97 | $-0.75 | $-0.86 | $-0.90 |
Low Forecast | $-4.53 | $-4.83 | $-3.87 | $-5.78 | $-5.20 | $-5.72 | $-5.73 | $-1.18 | $-1.31 | $-5.98 | $-5.95 | $-4.39 | $-1.06 | $-0.98 | $-4.76 | $-4.90 | $-4.99 | $-0.97 | $-0.56 | $-1.09 | $-0.88 | $-0.91 | $-0.97 | $-0.75 | $-0.86 | $-0.90 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 1.41% | 1.24% | 1.03% | -0.72% | 1.56% | 1.30% | 1.16% | 0.68% | 1.57% | 1.17% | 1.09% |
Forecast
BridgeBio Pharma Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
XFOR | X4 Pharmaceuticals | $0.37 | $3.67 | 891.89% | Buy |
INZY | Inozyme Pharma | $2.69 | $14.67 | 445.35% | Buy |
ABOS | Acumen Pharmaceuticals | $2.31 | $7.00 | 203.03% | Buy |
DAWN | Day One Biopharmaceuticals | $13.34 | $38.80 | 190.85% | Buy |
APLS | Apellis Pharmaceuticals | $27.75 | $74.50 | 168.47% | Buy |
TERN | Terns Pharmaceuticals | $5.71 | $14.25 | 149.56% | Buy |
BBIO | BridgeBio Pharma | $23.24 | $45.00 | 93.63% | Buy |
AMLX | Amylyx Pharmaceuticals | $5.19 | $6.67 | 28.52% | Buy |
BPMC | Blueprint Medicines | $96.62 | $109.71 | 13.55% | Buy |
PTCT | PTC Therapeutics | $42.89 | $46.50 | 8.42% | Hold |
KRYS | Krystal Biotech | $182.29 | $191.00 | 4.78% | Buy |
MDGL | Madrigal Pharmaceuticals | $329.24 | $315.75 | -4.10% | Buy |
KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |